β-Lactamase-mediated resistance and opportunities for its control

Journal of Antimicrobial Chemotherapy

Volumn 41, Issue SUPPL. D, 1998, Pages 25-41

  Livermore, David M ^a  

^a CENTRAL PUBLIC HEALTH LABORATORY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

6 AMINOPENICILLANIC ACID; 7 AMINOCEPHALOSPORANIC ACID; BACTERIAL ENZYME; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM;

ANTIBIOTIC RESISTANCE; DRUG STABILITY; REVIEW;

EID: 0031747315     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/41.suppl_4.25     Document Type: Review

References (84)

1. Li, X.-Z., Ma, D., Livermore, D. M. & Nikaido, H. (1994). Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: active efflux as a contributing factor to β-lactam resistance. Antimicrobial Agents and Chemotherapy 38, 1742-52.
2. Poole, K. (1994). Bacterial multidrug resistance: emphasis on efflux mechanisms and Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy 34, 453-6.
3. Bush, K., Jacoby, G. A. & Medeiros, A. A. (1995). A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrobial Agents and Chemotherapy 39, 1211-33.
4. Richmond, M. H. & Sykes, R. B. (1973). The β-lactamases of Gram-negative bacteria and their possible physiological role. Advances in Microbial Physiology 9, 31-88.
5. Bush, K. (1989). Characterization of β-lactamases. Antimicrobial Agents and Chemotherapy 33, 259-76.
6. Ambler, R. P. (1980). The structure of β-lactamases. Philosophical Transactions of the Royal Society of London, Series B, Biological Sciences 289, 321-31.
7. Zimmermann, W. & Rosselet, A. (1977). Function of the outer membrane of Escherichia coli as a permeability barrier to beta-lactam antibiotics. Antimicrobial Agents and Chemotherapy 12, 368-72.
8. Nikaido, H. & Normark, S. (1987). Sensitivity of Escherichia coli to various β-lactams is determined by the interplay of outer membrane permeability and degradation by periplasmic β-lactamases: a quantitative predictive treatment. Molecular Microbiology 1, 29-36.
9. Livermore, D. M. & Davy, K. W. M. (1991). Invalidity for Pseudomonas aeruginosa of an accepted model of bacterial permeability to β-lactam antibiotics. Antimicrobial Agents and Chemotherapy 35, 916-21.
10. Livermore, D. M. (1995). β-Lactamases in laboratory and clinical resistance. Clinical Microbiology Reviews 8, 557-84.
11. Sabath, L. D., Garner, C., Wilcox, C. & Finland, M. (1975). Effect of inoculum and of beta-lactamase on the anti-staphylococcal activity of thirteen penicillins and cephalosporins. Antimicrobial Agents and Chemotherapy 8, 344-9.
12. Fu, K. P. & Neu, H. C. (1978). Piperacillin, a new penicillin active against many bacteria resistant to other penicillins. Antimicrobial Agents and Chemotherapy 13, 358-67.
13. Williams, J. D. (1978). The correlation of in-vitro susceptibility tests with in-vivo results of antibiotic treatment. Scandinavian Journal of Infectious Diseases, Suppl. 13, 64-6.
14. Rice, L. B., Yao, J. D. C., Klimm, K., Eliopoulos, G. M. & Moellering, R. C. (1991). Efficacy of different β-lactams against an extended-spectrum β-lactamase-producing Klebsiella pneumoniae strain in the rat intra-abdominal abscess model. Antimicrobial Agents and Chemotherapy 35, 1243-4.
15. 2 and pH on the inhibition of TEM-1 and other β-lactamases by penicillanic acid sulfones. Antimicrobial Agents and Chemotherapy 36, 1870-6.
16. Cullmann, W. & Dick, W. (1985). Evidence for nonspecific induction of β-lactamase in overproducing variants of Enterobacter cloacae and Citrobacter freundii. European Journal of Clinical Microbiology 4, 34-40.
17. Lacey, R. W. (1984). Antibiotic resistance in Staphylococcus aureus and streptococci. British Medical Bulletin 40, 77-83.
18. Matthew, M. (1979). Plasmid-mediated β-lactamases of Gram-negative bacteria: properties and distribution. Journal of Antimicrobial Chemotherapy 5, 349-58.
19. Sanders, C. C. & Sanders, W. E. (1992). β-Lactam resistance in Gram-negative bacteria: global trends and clinical impact. Clinical Infectious Diseases 15, 824-39.
20. Chen, H. Y., Yuan, M., Ibrahim-Elmagboul, I. B. & Livermore, D. M. (1995). National survey of susceptibility to antimicrobials amongst clinical isolates of Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy 35, 521-34.
21. Livermore, D. M. (1991). β-Lactamases of Pseudomonas aeruginosa. Antibiotics and Chemotherapy 44, 215-20.
22. Fung, C.-P., Yeo, S. F. & Livermore, D. M. (1994). Susceptibility of Moraxella catarrhalis isolates to β-lactam antibiotics in relation to β-lactamase pattern. Journal of Antimicrobial Chemotherapy 33, 215-22.
23. Neu, H. C. (1982). What do β-lactamases mean for clinical efficacy? Infection 11, Suppl. 2, S74-80.
24. Frère, J.-M. (1995). Beta-lactamases and bacterial resistance to antibiotics. Molecular Microbiology 16, 385-95.
25. Abraham, E. P. (1987). Cephalosporins 1945-1986. Drugs 34, Suppl. 2, 1-14.
26. Hamilton-Miller, J. M. T. (1971). Use of Michaelis-Menten kinetics in the analysis of synergism between β-lactam antibiotics. Journal of Theoretical Biology 31, 171-6.
27. Livermore, D. M. (1985). Do β-lactamases trap cephalosporins? Journal of Antimicrobial Chemotherapy 15, 511-4.
28. Sanders, C. C. & Sanders, W. E. (1979). Emergence of resistance to cefamandole: possible role of cefoxitin-inducible β-lactamases. Antimicrobial Agents and Chemotherapy 15, 792-7.
29. Livermore, D. M. (1987). Clinical significance of β-lactamase induction and stable derepression in Gram-negative rods. European Journal of Clinical Microbiology 6, 439-45.
30. Chow, J. W., Fine, M. J., Shlaes, D. M., Quinn, J. P., Hooper, D. C., Johnson, M. P. et al. (1991). Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Annals of Internal Medicine 115, 585-90.
31. Burwen, D. R., Banerjee, S. N., Gaynes, R. P. & the National Nosocomial Infections Surveillance System. (1994). Ceftazidime resistance among selected nosocomial Gram-negative bacteria in the United States. Journal of Infectious Diseases 170, 1622-5.
32. Tzelepi, E., Tzouvelekis, L. S., Vatopoulos, A. C., Mentis, A. F., Tskaris, A. & Legakis, N. J. (1992). High prevalence of stably derepressed class I β-lactamase expression in multiresistant clinical isolates of Enterobacter cloacae from Greek hospitals. Journal of Medical Microbiology 37, 91-5.
33. CMY-1 gene and its relationship with other β-lactamase genes. Antimicrobial Agents and Chemotherapy 40, 1926-30.
34. Jacoby, G. A., Han, P., Alvarez, M. & Tenover, F. (1995). Survey of extended-spectrum β-lactamase (ESBL) production in US clinical isolates. In Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1995. Abstract C40, p. 46. American Society for Microbiology, Washington, DC.
35. Livermore, D. M. & Yuan, M. (1996). Antibiotic resistance and production of extended-spectrum β-lactamases amongst Klebsiella spp. from intensive care units in Europe. Journal of Antimicrobial Chemotherapy 38, 409-24.
36. Johnson, C. C., Livornese, L., Gold, M. J., Pitsakis, P. G., Taylor, S. & Levison, M. E. (1995). Activity of cefepime against ceftazidime-resistant Gram-negative bacilli using low and high inocula. Journal of Antimicrobial Chemotherapy 35, 765-73.
37. Philippon, A., Labia, R. & Jacoby, G. (1989). Extended-spectrum β-lactamases. Antimicrobial Agents and Chemotherapy 33, 1131-6.
38. Jacoby, G. A. & Medeiros, A. A. (1991). More extended-spectrum β-lactamases. Antimicrobial Agents and Chemotherapy 35, 1697-704.
39. Du Bois, S. K., Marriott, M. S. & Amyes, S. G. B. (1995). TEM-and SHV-derived extended-spectrum β-lactamases: relationship between selection, structure and function. Journal of Antimicrobial Chemotherapy 35, 7-22.
40. Sirot, D., Sirot, J., Labia, R., Morand, A., Courvalin, P., Darfeuille-Michaud, A. et al. (1987). Transferable resistance to third-generation cephalosporins in clinical isolates of Klebsiella pneumoniae: identification of CTX-1, a novel β-lactamase. Journal of Antimicrobial Chemotherapy 20, 323-34.
41. Casewell, M. W. & Desai, N. (1983). Survival of multiplyresistant Klebsiella aerogenes and other Gram-negative bacteria on finger-tips. Journal of Hospital Infection 4, 350-60.
42. Arlet, G., Rouveau, M., Casin, I., Bouvet, P. J. M., Lagrange, P. H. & Philippon, A. (1994). Molecular epidemiology of Klebsiella pneumoniae strains that produce SHV-4 β-lactamase and which were isolated in 14 French hospitals. Journal of Clinical Microbiology 32, 2553-8.
43. de Champs, C., Sirot, C., Chanal, C., Poupart, M. C., Dumas, M. P, & Sirot, J. (1991). Concomitant dissemination of three extended-spectrum β-lactamases among different Enterobacteriaceae isolated in a French hospital. Journal of Antimicrobial Chemotherapy 27, 441-57.
44. Petit, A., Gerbaud, G., Sirot, D., Courvalin, P. & Sirot, J. (1990). Molecular epidemiology of TEM-3 (CTX-1) β-lactamase. Antimicrobial Agents and Chemotherapy 34, 219-24.
45. Hibbert-Rogers, L. C., Heritage, J., Todd, N. & Hawkey, P. M. (1994). Convergent evolution of TEM-26, a β-lactamase with extended-spectrum activity. Journal of Antimicrobial Chemotherapy 33, 707-20.
46. Vatopoulos, A. C., Philippon, A., Tzouvelekis, L. S., Komninou, Z. & Legakis, N. J. (1990). Prevalence of a transferable SHV-5 type β-lactamase in clinical isolates of Klebsiella pneumoniae and Escherichia coli in Greece. Journal of Antimicrobial Chemotherapy 26, 635-48.
47. Bauernfeind, A., Rosenthal, E., Eberlein, E., Holley, M. & Schweighart, S. (1993). Spread of Klebsiella pneumoniae producing SHV-5 β-lactamase among hospitalized patients. Infection 21, 18-22.
48. Brun-Buisson, C., Legrand, P., Philippon, A., Montravers, F., Ansquer, M. & Duval, J. (1987). Transferable enzymatic resistance to third-generation cephalosporins during nosocomial outbreak of multiresistant Klebsiella pneumoniae. Lancet ii, 302-6.
49. Nordmann, P., Ronco, E., Naas, T., Duport, C., Michel-Briand, Y. & Labia, R. (1993). Characterization of a novel extended-spectrum β-lactamase from Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 37, 962-9.
50. Danel, F., Hall, L. M. C., Gur, D., Akalin, H. E. & Livermore, D. M. (1995). Transferable production of PER-1 β-lactamase in Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy 35, 281-94.
51. Vahaboglu, H., Hall, L M. C., Mulazimoglu, L., Dodanli, S., Yildirim, I. & Livermore, D. M. (1995). Resistance to extended-spectrum cephalosporins, caused by PER-1 β-lactamase in Salmonella typhimurium from Istanbul, Turkey. Journal of Medical Microbiology 43, 294-9.
52. PER-2, which encodes an extended-spectrum class β-lactamase. Antimicrobial Agents and Chemotherapy 40, 616-20.
53. Hall, L. M. C., Livermore, D. M., Gur, D., Akova, M. & Akalin, H. E. (1993). OXA-11, an extended-spectrum variant of OXA-10 (PSE-2) β-lactamase from Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 37, 1637-44.
54. Danel, F., Hall, L. M. C., Gur, D. & Livermore, D. M. (1995). OXA-14, another extended-spectrum variant of OXA-10 (PSE-2) β-lactamase from Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 39, 1881-4.
55. Danel, F., Hall, L. M. C., Gur, D. & Livermore, D. M. (1995). OXA-2-related β-lactamase giving ceftazidime resistance in P. aeruginosa from Turkey. In Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1995. Abstract C24, p. 43. American Society for Microbiology, Washington, DC.
56. Christensen, B. G. (1981). Structure-activity relationships in β-lactam antibiotics. In β-Lactam Antibiotics: Mode of Action, New Developments, and Future Prospects (Salton, M. R. J. & Shockman, G. D., Eds), pp. 101-22. Academic Press, New York.
57. Podglajen, I., Breuil, J. & Collatz, E. (1993). Insertion of a novel DNA sequence, IS1186, immediately upstream of the silent carbapenemase gene cfiA, promotes expression of carbapenem resistance in clinical isolates of Bacteroides fragilis. In Program and Abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1993. Abstract 587, p. 226. American Society for Microbiology, Washington, DC.
58. Watanabe, M., Iyobe, S., Inoue, M. & Mitsuhashi, S. (1991). Transferable imipenem resistance in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 35, 147-51.
59. Osano, E., Arakawa, Y., Wacharotayankun, R., Ohta, M., Horii, T., Ito, H. et al. (1994). Molecular characterization of an enterobacterial metallo-β-lactamase found in a clinical isolate of Serratia marcescens that shows imipenem resistance. Antimicrobial Agents and Chemotherapy 38, 71-8.
60. Yang, Y. J., Wu, P.-J. & Livermore, D. M. (1990). Biochemical characterization of a β-lactamase that hydrolyzes penems and carbapenems from two Serratia marcescens isolates. Antimicrobial Agents and Chemotherapy 34, 755-8.
61. Nordmann, P., Mariotte, S., Naas, T., Labia, R. & Nicholas, M. H. (1993). Biochemical properties of a carbapenem-hydrolyzing β-lactamase from Enterobacter cloacae and cloning of the gene into Escherichia coli. Antimicrobial Agents and Chemotherapy 37, 939-46.
62. Rasmussen, B. A., Keeney, D., Yang, Y., O'Gara, C., Bush, K. & Medeiros, A. A. (1994), Cloning, sequencing and biochemical characterization of a novel carbapenem-hydrolyzing β-lactamase from Enterobacter cloacae. In Program and Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, FL, 1994. Abstract C62, p. 89. American Society for Microbiology, Washington, DC.
63. Sabath, L D., Elder, H. A., McCall, C. E. & Finland, M. (1967). Synergistic combinations of penicillins in the treatment of bacteriuria. New England Journal of Medicine 277, 232-8.
64. Fisher, J., Belasco, J. G., Charnas, R. L, Khosla, S. & Knowles, J. R. (1980). β-Lactamase inactivation by mechanism-based reagents. Philosophical Transactions of the Royal Society of London, Series B, Biological Sciences 289, 309-19.
65. Bush, K. & Sykes, R. B. (1983). β-Lactamase inhibitors in perspective. Journal of Antimicrobial Chemotherapy 11, 97-107.
66. Livermore, D. M. (1993). Determinants of the activity of β-lactamase inhibitor combinations. Journal of Antimicrobial Chemotherapy 31, Suppl. A, 9-21.
67. Payne, D. J., Cramp, R., Winstanley, D. J. & Knowles, D. J. C. (1994). Comparative activities of clavulanic acid, sulbactam and tazobactam against clinically important β-lactamases. Antimicrobial Agents and Chemotherapy 38, 767-72.
68. Akova, M., Yang, Y. & Livermore, D. M. (1990). Interactions of tazobactam and clavulanate with inducibly-and constitutively-expressed Class I β-lactamases. Journal of Antimicrobial Chemotherapy 25, 199-208.
69. Coleman, K., Griffin, D. R. J., Page, J. W. J. & Upshon, P. A. (1989). In vitro evaluation of BRL 42715, a novel β-lactamase inhibitor. Antimicrobial Agents and Chemotherapy 33, 1580-7.
70. Angehrn, P. & Gutknecht, E. M. (1995). Bridged β-lactam Ro 48-1256. Antibacterial activity in combination with cephalosporins and imipenem. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA. Abstract F148, p. 138. American Society for Microbiology, Washington, DC.
71. Payne, D. J., Bateson, J. H., Gasson, B. C., Proctor, D., Khushi, T., Farmer, T. H. et al. (1997). Inhibition of metallo-β-lactamases by a series of mercaptoacetic acid thiol ester derivatives. Antimicrobial Agents and Chemotherapy 41, 135-40.
72. Livermore, D. M. & Seetulsingh, P. (1991). Susceptibility of Escherichia coli isolates with TEM-1 β-lactamase to combinations of BRL 42715, tazobactam or clavulanate with piperacillin or amoxycillin. Journal of Antimicrobial Chemotherapy 27, 761-7.
73. Seetulsingh, P. S., Hall, L. M. C. & Livermore, D. M. (1991). Activity of clavulanate combinations against TEM-1 β-lactamaseproducing Escherichia coli isolates obtained in 1982 and 1989. Journal of Antimicrobial Chemotherapy 27, 749-59.
74. Bonfiglio, G. & Livermore, D. M. (1993). Behaviour of β-lactamase-positive and -negative Staphylococcus aureus isolates in susceptibility tests with piperacillin/tazobactam and other β-Iactam/β-lactamase inhibitor combinations. Journal of Antimicrobial Chemotherapy 32, 431-44.
75. Urban, C., Go, E., Mariano, N., Berger, B. J., Avraham, I., Rubin, D. et al. (1993). Effect of sulbactam on infections caused by imipenem-resistant Acinetobacter calcoaceticus biotype anitratus. Journal of Infectious Diseases 167, 448-51.
76. Bonfiglio, G. & Livermore, D. M. (1994). β-Lactamase types amongst Staphylococcus aureus isolates in relation to susceptibility to β-lactamase inhibitor combinations. Journal of Antimicrobial Chemotherapy 33, 465-81.
77. Kemal, C. & Knowles, J. R. (1981). Penicillanic acid sulfone: interactions with RTEM β-lactamase from Escherichia coli at different pH values. Biochemistry 20, 3688-95.
78. Kuck, N. A., Jacobus, N. V., Petersen, P. J., Weiss, W. J. & Testa, R. T. (1989). Comparative in vitro and in vivo activities of piperacillin combined with the β-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam. Antimicrobial Agents and Chemotherapy 33, 1964-9.
79. Appelbaum, P. C. (1993). Comparative susceptibility profile of piperacillin/tazobactam against anaerobic bacteria. Journal of Antimicrobial Chemotherapy 31, Suppl. A, 29-38.
80. Chen, H. Y., Bonfiglio, G., Allen, M., Piper, D., Edwardson, T., McVey, D. et al. (1993). Multicentre survey of the comparative invitro activity of piperacillin/tazobactam against bacteria from hospitalized patients in the British Isles. Journal of Antimicrobial Chemotherapy 32, 247-66.
81. Bauernfeind, A. (1990). Perspectives of beta-lactamase inhibitors in therapy of infections caused by Escherichia coli or Klebsiella with plasmidic resistance to third-generation cephalosporins. Infection 18, 48-52.
82. Jacoby, G. A. & Carreras, I. (1990). Activities of β-lactam antibiotics against Escherichia coli strains producing extended-spectrum β-lactamases. Antimicrobial Agents and Chemotherapy 34, 858-62.
83. Henquell, C., Chanal, C., Sirot, D., Labia, R. & Sirot, J. (1995). Molecular characterization of nine different types of mutants among 107 inhibitor-resistant TEM β-lactamases from clinical isolates of Escherichia coli. Antimicrobial Agents and Chemotherapy 39, 427-30.
84. Spratt, B. G. (1994). Resistance to antibiotics mediated by target alterations. Science 264, 388-93.